Reports From the Field

Improving Nephropathy Screening in Appalachian Patients With Diabetes Using Practice-Wide Outreach


 

References

According to the Centers for Disease Control and Prevention (CDC), an estimated 30.3 million people in the United States—about 9.4% of the population—have been diagnosed with diabetes.1 Diabetes is the seventh leading cause of death in the United States, and it contributes to other leading causes of death: heart disease and stroke.1 Diabetes also is related to high morbidity risk and is a leading cause of chronic kidney disease.1 The total cost of diagnosed diabetes was estimated at $327 billion in direct medical costs and reduced productivity.2

Residents of Appalachia bear a disproportionate burden of diabetes and other related negative health outcomes; these outcomes are influenced by a number of factors, including socioeconomic status, poverty, rurality, and health care access. Rates of chronic disease, such as diabetes, are most pronounced in Appalachia’s most economically distressed counties.3-5 In 2011, the CDC labeled a 644-county area the “diabetes belt,” which included most of Appalachia.6 As a result of this elevated prevalence of diabetes in Appalachia as compared to the rest of the country, complications directly associated with diabetes are more commonly observed in Appalachian residents. One of the most damaging complications is diabetic nephropathy.

Diabetic nephropathy results from damage to the microvasculature of the kidney due to inadequately controlled blood glucose. This, in turn, leads to decreased renal function, eventually leading to clinically significant renal disease. The long-term complications associated with nephropathy can include many comorbid conditions, the most serious of which are progression to end-stage renal disease, dialysis requirement, and early mortality. Diabetic nephropathy affects approximately 40% of patients with type 1 and type 2 diabetes.7,8

Pages

Recommended Reading

SGLT2 inhibitors for diabetes safe, effective in older adults
Journal of Clinical Outcomes Management
Score predicts bariatric surgery’s benefits for obesity, type 2 diabetes
Journal of Clinical Outcomes Management
Carbohydrate restriction a viable choice for reversal of type 2 diabetes, expert says
Journal of Clinical Outcomes Management
Gout rates reduced with SGLT2 inhibitors
Journal of Clinical Outcomes Management
FDA warns of possible cancer risk with lorcaserin
Journal of Clinical Outcomes Management
Bariatric surgery is most effective early in the diabetes trajectory
Journal of Clinical Outcomes Management
Sarcopenia associated with increased cardiometabolic risk
Journal of Clinical Outcomes Management
FDA approves CV disease benefit for once-weekly semaglutide
Journal of Clinical Outcomes Management
Gestational diabetes: Treatment controversy rages on
Journal of Clinical Outcomes Management
Noninjectable modes of insulin delivery coming of age
Journal of Clinical Outcomes Management